European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
05 Sep 2007

COACH-study: results of subgroup analyses-heart failure - CLINICAL TRIAL UPDATE 2 

Tiny Jaarsma 

Tiny Jaarsma
Session number: 4503
Session title: Clinical Trial Update II
Authors: Jaarsma, Tiny (Netherlands)
Presenter report:
Jaarsma, Tiny (Netherlands)


The Coordinating study evaluating Outcomes of Advising and Counselling in Heart Failure (COACH) was a multicenter randomized controlled trial, in which 1023 patients were enrolled after hospitalization for HF.


Patients were assigned to one of three groups: a control group (follow-up by cardiologist), and two intervention groups with additional basic, or intensive support by a HF nurse.
Patients were studied for 18 months. Primary endpoints were time to death or rehospitalization for HF, and the number of days lost to death or hospitalization. Subgroup analysis were performed to determine possible heterogeneity in the effect of nurse-led heart failure care with regard to prespecified baseline variables.

During the study 411 patients (40%) were readmitted for HF or died from any cause: 42% in the control group, and 41% and 38% in the basic and intensive support groups, respectively (p=0.53).
The number of days lost to death or hospitalization was 39,960 in the control group, and it was 15% lower in the intervention groups combined (p=NS).
There was a trend towards lower mortality in the intervention groups combined (HR 0.85; 95%, p=0.18). Subgroup analyses revealed that no significant treatment x subgroup interaction was found except for an interaction between depression and all cause mortality.
Patients without depressive symptoms seem to benefit more from the basic or intensive support by a heart failure nurse compared to patients with depressive symptoms.
Further studies to determine the most optimal model for heart failure disease management are needed.


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.


 
Highlight On